2008 Top 20 Pharmaceutical Companies Report
The weak U.S. dollar played a strong role in this year’s Top 20 Pharma Report. Several overseas players look a lot better than they should, thanks to my insistence on converting all results to dollars. In local currencies, many foreign and domestic players were barely able to eke out growth in 2007. Several companies still managed to post solid gains during the year, but even they were haunted by the specter of patent expirations to come.
It was a tough year at many of these companies, with layoffs reaching the tens of thousands. New leadership teams, with chief executives not much older than your humble editor, have inherited truly untenable situations.
—Gil Y. Roth, Editor
|Top 20 Pharmaceutical Companies|
|07||Johnson & Johnson||$24,866|
|09||Eli Lilly & Co.||$17,638|
Based on 2007 pharma revenues.
Note: In all Top Company profiles, dollar amounts are in millions.
For the pipeline and patent expiry info, download the PDFs of the profiles, available within each company's page.
* PDF profiles only available for companies 17-20
Editor: Gil Y. Roth
Associate Editor: Kristin Brooks
Contributing Editor: Derek B. Lowe
All profiles written by Gil Roth, except Abbott Laboratories, by Kristin Brooks.
The Lowe Down capsules written by Derek Lowe
All pipeline information compiled by Kristin Brooks
Sales information compiled by Gil Roth
Looking for the Top 10 Biopharma companies report? Look no further!